Compare · head to head
Hanall Biopharma vs Ilsung IS
Ilsung IS ranks higher overall — 360 rank 59 vs 30.
Ilsung IS leads on Value (51 vs 40), Quality (50 vs 36) and Safety (50 vs 41). Hanall Biopharma leads on Sentiment (64 vs 59). The two are close on Growth.
Ranks as of 2026-06-12 · 1–100 vs true peers. Higher is better.
| Compare | ||
|---|---|---|
| Profile | ||
| Country | South Korea | South Korea |
| Sector | Health Care | Health Care |
| Industry | Pharmaceuticals | Pharmaceuticals |
| Size | Small | Small |
| ISIN | KR7009420001 | KR7003120003 |
| Last update | 2026-04-02 | 2026-04-02 |
| History | ||
| 360 (V1) since 2023 | — | |
| Ranks | ||
| 360 | 30 | 59 |
| Value | 40 | 51 |
| Quality | 36 | 50 |
| Growth | 48 | 48 |
| Safety | 41 | 50 |
| Sentiment | 64 | 59 |
| Quality details | ||
| Profitability | 38 | 47 |
| Cash Truth | 34 | 53 |
Hanall Biopharma vs Kukje PharmaHanall Biopharma vs Dongwha PharmHanall Biopharma vs Bora PharmaceuticalsHanall Biopharma vs Jeil PharmaAdd a third stock →
Full analyses: Hanall Biopharma · Ilsung IS
Make Sense of the Ranks
Every rank runs 1–100 against true peers. Higher is always better.
360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100